CVS Health (CVS) Stock Forecast & Price Target

$67.75 -0.32 (-0.47%)

As of 09:36 AM Eastern

CVS Health - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 21 Analyst Ratings

Sell
0

Hold
3

Buy
18

Based on 21 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 3 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for CVS.

Consensus Price Target

$70.41
3.93% Upside

According to the 21 analysts' twelve-month price targets for CVS Health, the average price target is $70.41. The highest price target for CVS is $81.00, while the lowest price target for CVS is $58.00. The average price target represents a forecasted upside of 3.93% from the current price of $67.75.

Get the Latest News and Ratings for CVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CVS Health and its competitors.

CVS Analyst Ratings Over Time

Type	Current Forecast 4/3/24 to 4/3/25	1 Month Ago 3/4/24 to 3/4/25	3 Months Ago 1/4/24 to 1/3/25	1 Year Ago 4/4/23 to 4/3/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	17 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	6 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$70.41	$69.82	$69.12	$89.44
Forecasted Upside	3.93% Upside	8.66% Upside	51.01% Upside	19.87% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Remove Ads

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CVS Health Stock vs. The Competition

Type	CVS Health	Medical Companies	S&P 500
Consensus Rating Score	2.90	2.81	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	3.33% Upside	19,056.16% Upside	17.75% Upside
News Sentiment Rating	Positive News See Recent CVS News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/21/2025	Piper Sandler 2 of 5 stars	Jessica Tassan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$72.00 ➝ $74.00	+7.70%
2/18/2025	Argus 2 of 5 stars		Set Target		$77.00	+16.93%
2/18/2025	JPMorgan Chase & Co. 3 of 5 stars	Lisa Gill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$80.00 ➝ $81.00	+23.71%
2/13/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$68.00 ➝ $73.00	+11.76%
2/13/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Macdonald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$60.00 ➝ $76.00	+20.20%
2/13/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Mok Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$71.00 ➝ $73.00	+15.45%
2/13/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$55.00 ➝ $75.00	+18.61%
2/12/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
2/12/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
2/11/2025	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	67.00 ➝ 70.00
Get the Latest News and Ratings for CVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CVS Health and its competitors with MarketBeat's FREE daily newsletter.
2/11/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$62.00 ➝ $59.00	+7.25%
1/30/2025	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
1/27/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Elizabeth Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$60.00 ➝ $65.00	+15.59%
12/3/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$66.00 ➝ $66.00	+11.73%
11/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Rhyee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$73.00 ➝ $80.00	+33.11%
11/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$68.00 ➝ $58.00	+8.33%
10/24/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$73.00 ➝ $66.00	+16.24%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$61.00	+13.55%
5/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$95.00 ➝ $77.00	+41.73%
5/2/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$85.00 ➝ $74.00	+36.08%
12/22/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$94.00	+19.56%
11/2/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$110.00 ➝ $100.00	+43.55%
10/10/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$93.00 ➝ $80.00	+11.41%
8/4/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$90.00 ➝ $85.00	+14.34%
5/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$125.00 ➝ $96.00	+35.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:30 AM ET.

Should I Buy CVS Health Stock? CVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, March 30, 2025. Please send any questions or comments about these CVS Health pros and cons to contact@marketbeat.com.

CVS Health
Bull Case

Here are some ways that investors could benefit from investing in CVS Health Co.:

CVS Health Co. has recently seen a significant increase in institutional investment, with 80.66% of its stock owned by institutional investors, indicating strong confidence in the company's future performance.
The stock price is currently around $66.70, which is near the higher end of its one-year range of $43.56 to $79.98, suggesting potential for growth as it approaches its previous highs.
Analysts have a consensus rating of "Moderate Buy" for CVS Health Co., with an average price target of $70.39, indicating that many experts believe the stock is undervalued and has room for appreciation.
The company reported earnings per share of $1.19, exceeding the consensus estimate by $0.30, which reflects strong operational performance and profitability.
CVS Health Co. has a solid dividend yield of 3.96%, providing investors with a reliable income stream, which is particularly attractive in a low-interest-rate environment.

CVS Health
Bear Case

Investors should be bearish about investing in CVS Health Co. for these reasons:

The company has a relatively high debt-to-equity ratio of 0.80, which may indicate that it is relying on debt to finance its operations, potentially increasing financial risk.
Despite recent positive earnings, CVS Health Co. has a net margin of only 1.24%, suggesting that profitability may be constrained, which could limit future growth opportunities.
Recent insider trading activity shows that a senior vice president sold a significant number of shares, which could signal a lack of confidence in the company's short-term prospects.
The stock's beta of 0.54 indicates lower volatility compared to the market, which may limit potential gains during bullish market conditions.
With a payout ratio of 72.68%, a significant portion of earnings is being distributed as dividends, which may restrict the company's ability to reinvest in growth initiatives.

CVS Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $70.41, with a high forecast of $81.00 and a low forecast of $58.00.
: 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last year. There are currently 3 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CVS shares.
: According to analysts, CVS Health's stock has a predicted upside of 3.93% based on their 12-month stock forecasts.
: Over the previous 90 days, CVS Health's stock had 4 upgrades by analysts.
: CVS Health has been rated by research analysts at Argus, Barclays, Cantor Fitzgerald, Edward Jones, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Piper Sandler, Truist Financial, UBS Group, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like CVS Health more than other "medical" companies. The consensus rating score for CVS Health is 2.90 while the average consensus rating score for "medical" companies is 2.82. Learn more on how CVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:CVS) was last updated on 4/3/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CVS Health (CVS) Stock Forecast & Price Target